Tirzepatide, a drug for diabetes and weight loss, may help reduce OSA severity, offering a possible pharmaceutical solution for this condition without treatment currently available.
Research conducted by an international team, including scientists at Lilly, showed promising results from two phase three trials involving obesity and OSA patients receiving tirzepatide injections.
Collection
[
|
...
]